A trial of GR-MD-02 in patients with atopic dermatitis
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2017
At a glance
- Drugs GR MD 02 (Primary)
- Indications Atopic dermatitis; Eczema
- Focus Therapeutic Use
- 14 Aug 2017 Status changed from recruiting to completed according to a Galectin Therapeutics media release.
- 17 Mar 2017 New trial record
- 14 Mar 2017 According to a Galectin Therapeutics media release, Simon A. Ritchie, M.D., FAAD is the lead investigator of this trial.